JP2023513906A5 - - Google Patents
Info
- Publication number
- JP2023513906A5 JP2023513906A5 JP2022548997A JP2022548997A JP2023513906A5 JP 2023513906 A5 JP2023513906 A5 JP 2023513906A5 JP 2022548997 A JP2022548997 A JP 2022548997A JP 2022548997 A JP2022548997 A JP 2022548997A JP 2023513906 A5 JP2023513906 A5 JP 2023513906A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- compound
- tautomer
- salt
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20157257 | 2020-02-13 | ||
| EP20157257.5 | 2020-02-13 | ||
| PCT/EP2021/053284 WO2021160716A1 (en) | 2020-02-13 | 2021-02-11 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023513906A JP2023513906A (ja) | 2023-04-04 |
| JP2023513906A5 true JP2023513906A5 (https=) | 2024-01-26 |
| JP7686002B2 JP7686002B2 (ja) | 2025-05-30 |
Family
ID=69591570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022548997A Active JP7686002B2 (ja) | 2020-02-13 | 2021-02-11 | 血漿カリクレイン阻害剤としての複素芳香族カルボキサミド誘導体 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11851418B2 (https=) |
| EP (1) | EP4103561A1 (https=) |
| JP (1) | JP7686002B2 (https=) |
| CN (1) | CN115087652B (https=) |
| AR (1) | AR121340A1 (https=) |
| TW (1) | TW202144331A (https=) |
| WO (1) | WO2021160716A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112839711A (zh) | 2018-10-10 | 2021-05-25 | 勃林格殷格翰国际有限公司 | 作为血浆激肽释放酶抑制剂的苯基四唑衍生物 |
| TWI873290B (zh) | 2020-02-13 | 2025-02-21 | 德商百靈佳殷格翰國際股份有限公司 | 作為血漿激肽釋放酶抑制劑之雜芳族甲醯胺衍生物 |
| TW202144331A (zh) | 2020-02-13 | 2021-12-01 | 德商百靈佳殷格翰國際股份有限公司 | 作為血漿激肽釋放酶抑制劑之雜芳族甲醯胺衍生物 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI243164B (en) | 2001-02-13 | 2005-11-11 | Aventis Pharma Gmbh | Acylated indanyl amines and their use as pharmaceuticals |
| US20050090529A1 (en) | 2003-07-31 | 2005-04-28 | Pfizer Inc | 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation |
| JP2005089362A (ja) | 2003-09-17 | 2005-04-07 | Sumitomo Chemical Co Ltd | アリールピラゾリン化合物及びその用途 |
| EP2259679A4 (en) | 2008-01-31 | 2011-09-14 | Joslin Diabetes Ct | METHODS OF TREATING KALLIKREIN RELATED DISORDERS |
| EP2807156A1 (en) | 2012-01-27 | 2014-12-03 | Novartis AG | Aminopyridine derivatives as plasma kallikrein inhibitors |
| US20140378474A1 (en) | 2012-01-27 | 2014-12-25 | Novartis Ag | 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors |
| EP2999697B1 (en) | 2013-05-23 | 2017-04-19 | Kalvista Pharmaceuticals Limited | Heterocyclic derivates |
| KR102736869B1 (ko) * | 2014-03-07 | 2024-12-02 | 바이오크리스트파마슈티컬즈,인코포레이티드 | 인간 혈장 칼리크레인 저해제 |
| GB201421083D0 (en) * | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
| DK4019022T3 (en) * | 2015-10-01 | 2024-02-19 | Biocryst Pharm Inc | Human plasma kallikrein inhibitors |
| WO2017072020A1 (en) | 2015-10-27 | 2017-05-04 | Boehringer Ingelheim International Gmbh | Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors |
| EP3368524B1 (en) | 2015-10-27 | 2021-08-18 | Boehringer Ingelheim International GmbH | Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors |
| DK3464271T3 (da) | 2016-05-31 | 2020-06-15 | Kalvista Pharmaceuticals Ltd | Pyrazolderivater som plasma-kallikreininhibitorer |
| CN110022875A (zh) | 2016-07-11 | 2019-07-16 | 莱福斯希医药公司 | 治疗性抑制化合物 |
| US10501440B2 (en) | 2017-04-21 | 2019-12-10 | Boehringer Ingelheim International Gmbh | Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors |
| JP6828191B2 (ja) * | 2018-08-16 | 2021-02-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 血漿カリクレイン阻害剤としての複素芳香族カルボキサミド誘導体 |
| DK4031547T3 (da) * | 2019-09-18 | 2024-09-09 | Takeda Pharmaceuticals Co | Plasmakallikreininhibitorer og anvendelser deraf |
| TW202144331A (zh) | 2020-02-13 | 2021-12-01 | 德商百靈佳殷格翰國際股份有限公司 | 作為血漿激肽釋放酶抑制劑之雜芳族甲醯胺衍生物 |
| TWI873290B (zh) | 2020-02-13 | 2025-02-21 | 德商百靈佳殷格翰國際股份有限公司 | 作為血漿激肽釋放酶抑制劑之雜芳族甲醯胺衍生物 |
-
2021
- 2021-02-09 TW TW110104876A patent/TW202144331A/zh unknown
- 2021-02-11 US US17/173,212 patent/US11851418B2/en active Active
- 2021-02-11 EP EP21704539.2A patent/EP4103561A1/en active Pending
- 2021-02-11 WO PCT/EP2021/053284 patent/WO2021160716A1/en not_active Ceased
- 2021-02-11 JP JP2022548997A patent/JP7686002B2/ja active Active
- 2021-02-11 CN CN202180014104.6A patent/CN115087652B/zh active Active
- 2021-02-12 AR ARP210100384A patent/AR121340A1/es not_active Application Discontinuation